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Previous studies have shown that the protease-acti-
vated receptor 2 is involved in skin pigmentation
through increased phagocytosis of melanosomes by
keratinocytes. Ultraviolet irradiation is a potent
stimulus for melanosome transfer. We show that
protease-activated receptor 2 expression in human
skin is upregulated by ultraviolet irradiation.
Subjects with skin type I, II, or III were exposed to
two or three minimal erythema doses of irradiation
from a solar simulator. Biopsies were taken from
nonexposed and irradiated skin 24 and 96 h after
irradiation and protease-activated receptor 2 expres-
sion was detected using immunohistochemical stain-
ing. In nonirradiated skin, protease-activated
receptor 2 expression was con®ned to keratinocytes
in the lower one-third of the epidermis. After ultra-
violet irradiation protease-activated receptor 2
expression was observed in keratinocytes in the
upper two-thirds of the epidermis or the entire epi-
dermis at both time points studied. Subjects with
skin type I showed delayed upregulation of protease-
activated receptor 2 expression, however, compared
with subjects with skin types II and III. Irradiated
cultured human keratinocytes showed upregulation
in protease-activated receptor 2 expression as deter-
mined by immuno¯uorescence microscopy and
Western blotting. Cell culture supernatants from
irradiated keratinocytes also exhibited a dose-
dependent increase in protease-activated receptor-2
cleavage activity. These results suggest an important
role for protease-activated receptor-2 in pigmenta-
tion in vivo. Differences in protease-activated recep-
tor 2 regulation in type I skin compared with skin
types II and III suggest a potential mechanism for
differences in tanning in subjects with different skin
types. Key words: keratinocytes/melanosome/protease-acti-
vated receptor-2 (PAR-2)/UV irradiation. J Invest
Dermatol 117:1412±1420, 2001
P
rotease-activated receptor-2 (PAR-2) is a member of a
novel G-protein-coupled seven transmembrane receptor
family (reviewed by Dery et al, 1998). These receptors
are irreversibly activated through proteolytic cleavage of
the amino terminus. Subsequent to proteolytic cleavage,
the newly exposed NH2 terminus acts as a tethered peptide ligand,
which binds and activates the receptor. Four protease-activated
receptors have been cloned to date (Vu et al, 1991; Nystedt et al,
1994; Ishihara et al, 1997; Xu et al, 1998) and are characterized by
their sensitivity to activation by thrombin and trypsin. PAR-1 and
PAR-3 are activated by thrombin (Vu et al, 1991; Ishihara et al,
1997), whereas PAR-4 is activated by both thrombin and trypsin
(Xu et al, 1998). In HaCaT cells PAR-2 is activated by trypsin,
mast cell tryptase, and factor VIIa or factor Xa (Kong et al, 1997;
Smith-Swntosky et al, 1997; Camerer et al, 2000). In neuronal cells
PAR-2 can be activated by the neuronal growth-associated protein
B-50/GAP-43 (Hollenberg et al, 2000).
PAR-2 is widely distributed in the body including gastro-
intestinal tract, pancreas, kidney, liver, lung, cardiovascular system,
ovary, eye, and brain (Nystedt et al, 1995a; 1995b; 1994; Bohm et
al, 1996a; D'Andrea et al, 1998). It is expressed by epithelial cells
(keratinocytes, epithelial-derived tumor cells), endothelial cells,
enterocytes, smooth muscle cells, neutrophils, neurons, and T cell
lines (Mari et al, 1996). The endogenous activator for PAR-2 in the
epidermis remains to be de®ned, but because tissue distribution of
PAR-2 expression is not limited to the gastrointestinal system
where luminal trypsin is present, it has been suggested that trypsin-
like enzymes such as mast cell tryptase may activate PAR-2
(Molino et al, 1997). Mast cell tryptase has been shown to cleave
and activate PAR-2 in cells that express the receptor (Mari et al,
1996; Corvera et al, 1997; Molino et al, 1997), including
keratinocytes (Santulli et al, 1995; Molino et al, 1997; Schechter
et al, 1998; Steinhoff et al, 1999). PAR-2 is also activated by a
synthetic peptide SLIGRL, which corresponds to the cleaved N
terminus, independent of receptor cleavage (Steinhoff et al, 1999).
The mouse peptide (SLIGRL) is equipotent to the human peptide
(SLIGKV) in activating the human PAR-2 (Nystedt et al, 1995b;
Bohm et al, 1996a). In human keratinocytes, activation of PAR-2
results in Ca2+ mobilization (Bohm et al, 1997).
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PAR-2 is involved in a broad spectrum of physiologic processes,
including growth and development, mitogenesis, injury responses,
and cutaneous pigmentation. PAR-2 activation stimulates MAP
kinase in some cell types, resulting in proliferation, whereas in
keratinocytes PAR-2 inhibits growth and differentiation (Derian et
al, 1997). Human dermal ®broblasts, which express PAR-2 or a
PAR-2-like receptor, show concentration-dependent increases in
proliferation in response to mast cell tryptase (Akers et al, 2000). In
enterocytes PAR-2 activation induces arachidonic acid release,
eicosanoid generation, and cyclooxygenase-2 expression (Kong et
al, 1997). In neutrophils, bacterial proteinases activate PAR-2,
which stimulates Ca2+ in¯ux and increased expression of the
CD11b adhesion molecule (Vu et al, 1991). In rat heart, PAR-2
activation protects against reperfusion injury (Napoli et al, 1999).
This effect is coupled to elevation of PAR-2 and tumor necrosis
factor a (TNF-a) expression. Studies have shown that PAR-2
mRNA is upregulated by TNF-a and interleukin-1 (IL-1) in
vascular endothelial cells (Nystedt et al, 1996). PAR-2 de®cient
mice show delayed onset of leukocyte rolling in response to trauma
due to absence of PAR-2-induced p-selectin expression (Lindner et
al, 2000). In keratinocytes, PAR-2 activation stimulates secretion of
IL-6 and granulocyte macrophage colony stimulating factor
(GMCSF; Wakita et al, 1997). Furthermore, in several recent
studies Seiberg et al (2000a) and Sharlow et al (2000) demonstrated
that, in keratinocyte±melanocyte cocultures, PAR-2 activation
induced melanosome transfer through increased keratinocytic
phagocytosis of melanosomes. In addition, the same group
provided evidence that PAR-2 affects pigmentation via modulation
of melanosome uptake in vivo. They showed that serine protease
inhibitors that interfere with PAR-2 activation induced a dose-
dependent depigmentation of the skin of dark-skinned Yucatan
swine. The inhibitors work by inhibiting melanosome transfer and
distribution, which leads to skin lightening in vivo (Seiberg et al,
2000b). Moreover, inhibition of PAR-2 activation prevented
ultraviolet B (UVB) induced pigmentation both in vitro and in vivo
(Seiberg et al, 2000b; Paine et al, 2001). Interestingly, treatment of
epidermal equivalents with trypsin, a serine protease that activates
PAR-2, induced pigmentation to the same level as observed with
UV irradiation (Seiberg et al, 2000b). These data suggest an
important role for PAR-2 as a cytokine-inducible in¯ammatory
mediator in the skin and as a protein involved in epidermal
pigmentation.
UV irradiation of keratinocytes stimulates pigmentation in
human skin through multiple mechanisms including upregulation
of key melanogenic enzymes, DNA photodamage, which directly
results in melanogenesis, increased melanosome transfer to
keratinocytes, and increased melanocyte dendricity (Pathak et al,
1965; 1978; Sturm, 1998; Gilchrest and Eller, 1999; Park and
Gilchrest, 1999). A recent report suggests that UV radiation (UVR)
may regulate skin pigmentation through downregulation of
neprilysin, a neutral endopeptidase that degrades melanocortin
(Aberdam et al, 2000). It is well known that individuals with skin
type I tan poorly compared with individuals with skin types II and
III. Because previous studies have shown that activation of PAR-2
induces melanosome transfer in vivo, because inhibition of PAR-2
activation prevents UVB-induced pigmentation, and because UVR
is a potent stimulus for melanosome transfer in vivo, we
hypothesized that UVR might upregulate PAR-2 expression
in vivo. Furthermore, we hypothesized that differences in regulation
of PAR-2 in response to UVR may contribute to differences in
tanning in individuals with different skin types. We examined the
effect of UVR on the expression of PAR-2 in epidermis in subjects
with type I, II, or III skin in vivo. We show that UVR elicits an
increase in PAR-2 protein expression in human skin, suggesting a
role for PAR-2 in melanosome transfer in vivo in response to UVR.
We also demonstrate differences in PAR-2 regulation among
subjects with type I skin compared with types II and III skin.
Irradiation of cultured human keratinocytes resulted in upregula-
tion of PAR-2 protein by immuno¯uorescence microscopy and
Western blotting, and induced a dose-dependent increase in
secreted proteases with PAR-2 cleavage activity. These results
support a mechanism for UVR-induced PAR-2 upregulation and
activation in skin and suggest a potential mechanism for skin-type-
related responses to UVR in vivo.
MATERIALS AND METHODS
Subject For analysis of the effects of UVR on PAR-2 expression, 36
subjects were used. The subjects ranged in age from 22 to 67 y and
there were 12 men and 24 women. Each subject was evaluated by a
dermatologist (AP) and subjects were divided into three groups based on
skin type according to the Fitzpatrick standard criteria (Fitzpatrick,
1988). Twelve subjects for each skin type were examined for the work
presented here. None of the female participants was pregnant or took
oral contraceptives. To determine the minimum erythema dose (MED)
12 doses of UVA/UVB irradiation (290±400 nm) from 20 mJ to 300 mJ
(the dose range was adjusted for the subject's skin type) were
administered in graded doses to buttock skin using a 1000 W xenon arc
lamp solar simulator. The solar simulator was equipped with a UVC
WG320 and visible cutoff ®lter UG11, beam turner, and cooling fan.
The output was monitored by an IL 1700 radiometer and SED400
sensor probe purchased from International Light (Newburyport, MA).
Twenty-four hours after administration of light, biopsies of control and 3
MED irradiated skin were obtained. Ninety-six hours following
administration of UVR, a second control biopsy and a biopsy from 2
MED irradiated skin were obtained. The nonirradiated control skin sites
were 3 cm from the irradiated skin sites. The tissues were ®xed
immediately in 10% formalin and the four biopsies from each patient
were embedded into the same paraf®n block. In the second arm, subjects
received either placebo or Celecoxib and 10 d later irradiation and
measurement of erythema was repeated as above. Data from the second
arm of the study are not analyzed here.
Antibodies and reagents Rabbit PAR-2 polyclonal antibody was
raised against human PAR-2 peptide fragment (37SLGKVDGTSH-
VTGKG47V) by Research Genetics (Huntville, AL). This sequence is
present in both cleaved and uncleaved receptors and therefore the
antibody recognizes both active and inactive PAR-2. Monoclonal
antibody to human PAR-2 raised in goat was purchased from Research
Diagnostics (Flanders, NJ). Mouse monoclonal antibodies to proliferating
cell nuclear antigen (PCNA) were obtained from Santa Cruz
Biotechnology (Santa Cruz, CA; clone PC10; Ann Arbor, MI). Ki-67
(clone MIB-1) mouse monoclonal antibody was purchased from
Biogenex (San Ramon, CA). The Ki-67 antigen is a nuclear nonhistone
protein expressed by cells in the proliferative phases of the cell cycle. p53
mouse monoclonal antibody (clone 1801) was purchased from Oncogene
Science (Cambridge, MA). Polyclonal antibodies to trypsin were
purchased from Biogenesis (Kingston, NH). Tryspin, used as a positive
control, was purchased from Gibco-BRL (Grand Island, NY).
Keratinocyte serum free medium (SFM) was obtained from Gibco-BRL.
Biotinylated goat-antirabbit IgG and rabbit-antigoat IgG were obtained
from Vector Laboratories (Burlingame, CA) and permanox Laboratory-
Tek II chamber slides were obtained from Nalge Nunc International
(Naperville, IL). Texas Red-conjugated goat antirabbit antibodies were
purchased from Molecular Probes (Eugene, OR). Horseradish peroxidase
conjugated antibodies against goat immunoglobulin were purchased from
Vector Laboratories. Normal goat serum was purchased from Sigma (St.
Louis, MO). Streptavidin horseradish peroxidase was obtained from
Jackson Laboratories (Westgrove, PA). Aminoethylcarbizol chromogen
was obtained from Soy Tek (Utah). Centricon-10 ®lters were purchased
from Amicon (Beverly, MA).
Immunohistochemistry staining For PAR-2 staining, paraf®n
blocks were sectioned at 4 mm and placed on slides coated with poly L-
lysine (Sigma). Antigen unmasking with heat retrieval in citrate buffer
(pH 6.5) was accomplished by placing the slides in a microwave pressure
cooker (1500 W at power level 6) for 30 min. Normal goat serum (10%
in Tris-buffered saline) was used to block the nonspeci®c antibody
binding. PAR-2 polyclonal antibody (1:5000) in antibody stabilizer
(Dako, Carpinteria, CA) was applied at 4°C overnight. Secondary
antibodies were incubated at room temperature for 30 min. Streptavidin
horseradish peroxidase was applied for 30 min at room temperature. The
reaction was developed with aminoethylcarbizol and the slides were
counterstained in Mayer's hematoxylin. Negative controls consisted of
preimmune serum from the same rabbit that gave rise to the primary
antibody.
For Ki-67 staining, standard immunohistochemistry procedures were
followed as described previously (Manne et al, 1997). Paraf®n blocks were
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sectioned at 4 mm and attached to SuperFrost/Plus slides (Fisher Scienti®c,
Norcross, GA) by heating at 58°C for 1 h. After deparaf®nization and
rehydration the sections were transferred to a Tris-buffer bath (0.05 M
Tris base, 0.15 M NaCl, 0.0002% Triton X-100, pH 7.6). High tempera-
ture antigen recovery was followed as described previously (Grizzle et al,
1998). Each section was treated with hydrogen peroxide to quench
endogenous peroxidase activity and incubated with normal goat serum at
room temperature for 1 h in order to reduce nonspeci®c immunostaining.
Ki-67 primary antibodies were added at dilutions of 1:50. Staining for
PCNA and p53 was identical to that described above for Ki-67 with the
exception that the tissue was not heated. PCNA and p53 antibodies were
used at a dilution of 0.03 mg per ml and 0.5 mg per ml, respectively.
Negative controls remained in the goat serum (3%) at room temperature
for 1 h. The primary antibodies were detected using a multispecies
detection system from Signet Laboratories (Dedham, MA) according to
the manufacturer's instruction with diaminobenzidine tetrachloride as
chromogen. Each section was counterstained using hematoxylin.
Statistical analysis for immunocytochemical data For analysis of
PAR-2 expression, the slides were examined by two pathologists (ACD
and GS) independently and PAR-2 staining was graded as follows: level
I, expression in the basal keratinocytes and ®rst layer above the basal
layer; level II, expression in the basal and suprabasal keratinocytes
encompassing two-thirds of the epidermis; level III, staining throughout
the entire epidermis including the granular layer. Intensity of staining
was graded on a scale of 0 (no staining) to 4+ (strongest intensity).
Therefore, for each tissue section, two data points were obtained: level
of staining (I, II, III) and intensity of staining (0±4+). In the case of
nonconcordance in grading of a biopsy, the biopsy was reviewed and a
grade was assigned based on discussion between the two observers.
Concordance in grading of the cases was 90% between the two
observers. The data were analyzed with Wilcoxon signed rank and
Kruskal±Wallis c2 tests. p < 0.05 was considered as statistically signi®cant.
For analysis of PCNA, p53, and Ki-67 immunostaining, slides were
scored by a minimum of two evaluators (CRB, WB, or WEG). The
cells were classi®ed with respect to the intensity of immunostaining for
each antigen and with respect to the percentage of cells stained at each
level of intensity. Each evaluator estimated the intensity of the
immunostaining on a scale of 0 (no staining) to 4+ (strongest intensity).
In addition, each evaluator estimated the absolute percentage of cells
stained at each level of intensity. The percentage of cells at each level of
intensity was multiplied by the appropriate intensity score to obtain a
weighted average of the intensity score. The data were analyzed using
the Wilcoxon signed rank test for paired comparisons. p < 0.05 was
considered as statistically signi®cant.
Cell culture, UV irradiation, immuno¯uorescence microscopy, and
Western blotting Neonatal foreskins were obtained according to the
University of Rochester Research Subjects Review Board and were the
source of human keratinocytes. Epidermal suspensions were cultured in
keratinocyte SFM as previously described (Scott and Haake, 1991). For
immuno¯uorescence microscopy, keratinocytes were subcultured onto
permanox slides (104 cells per well) and were irradiated 24 h later. The
source of UVR was a 1000 W Oriel Xenon Arc Solar Simulator with
UVC WG320 and Visible Cutoff Filter UG11, beam turner, and cooling
fan. This produces electromagnetic irradiation from 295 nm (UVB) to
400 nm (UVA) and produces 3.75 3 10±3 W per cm2. The output was
monitored by an IL 1700 radiometer and SED400 sensor probe
purchased from International Light. During UVR, medium was replaced
with phosphate-buffered saline (PBS) containing Ca2+ and Mg2+. The
PBS was then replaced with culture medium and the cells were allowed
to grow at 37°C with 5% CO2 for 24 h before staining for PAR-2. The
slides were ®xed in 4% formalin in PBS for 15 min at room temperature
and incubated with 10% normal goat serum to block nonspeci®c
binding. Polyclonal PAR-2 antibody (1:500) was added to the slides and
allowed to incubate overnight at 4°C. After washing with PBS, Texas
Red-conjugated goat antirabbit antibody was placed on the slides for
60 min at room temperature, followed by three washes with PBS. Slides
were cover slipped with DAPI mounting media (Vector Laboratories)
and antifade reagent (Molecular Probes). The slides were then examined
using a Nikon Eclipse 800 immuno¯uorescence microscope and digital
photographs were taken with a SpotTM Cooled color digital camera
(Diagnostic Instruments, Sterling Heights, MI). Negative controls
consisted of cells incubated with preimmune serum instead of primary
antibodies. Experiments on three separate foreskin cultures were
performed.
For Western blotting, equal numbers of keratinocytes were cultured in
60 mm dishes until 80% con¯uent in SFM. Cells were irradiated with
1 J per cm2, 2 J per cm2, or 4 J per cm2, or sham irradiated with a solar
simulator. In preliminary experiments, trypan blue exclusion studies were
performed on irradiated cells to determine if irradiation resulted in
toxicity. There was no evident cell death associated with any of the
doses of UVR used. Twenty-four hours later culture supernatant was
analyzed for protease and PAR-2 cleavage activity (see below). The cells
were lyzed in RIPA buffer [150 mM NaCl, 1% Nonidet P-40, 0.5%
deoxycholate (DOC), 0.1% sodium dodecyl sulfate (SDS), 50 mM Tris-
HCl] with protease inhibitors (Boehringer Mannheim, Germany).
Protein was quantitated using bovine serum albumen as standard (Bio-
Rad Laboratories, Hercules, CA) and 50 mg was resolved on precast 10%
SDS polyacrylamide gels (Jule, New Haven, CT). Following transfer to
nitrocellulose membranes (Bio-Rad) and blocking overnight with 10%
nonfat milk in Tris-buffered saline membranes were incubated with
monoclonal antibodies to PAR-2 (1/5000) for 2 h at room temperature.
Following washes, the reaction product was detected with an enhanced
chemiluminescence reaction (Amersham Life Sciences) by exposing the
membranes to Kodak XAR ®lm (Rochester, NY). Assessment of lane
loading was accomplished by staining the gel with Coomasie Brilliant
Blue following transfer. Experiments on three separate foreskin cultures
were performed.
Protease and PAR-2 cleavage assay Total protease activity was
measured using the EnzChek protease assay kit, following the
manufacturer's instructions (Molecular Probes). Samples were incubated
with BODIPY ¯uorescent casein substrate at room temperature for 1 h
Figure 1. Distribution of PAR-2 in normal skin. (a) Biopsy from a subject with type II skin stained with polyclonal PAR-2 antibodies shows
strong staining of the basal keratinocytes. Hair follicle keratinocytes are also stained (arrow) as are endothelial cells (arrowhead). Scattered dermal dendritic
cells are also stained. (b) Higher magni®cation shows details of epidermal staining. Staining is predominantly cytoplasmic and is localized to the basal
layer of the epidermis. (c) Biopsy from the same patient stained with preimmune serum. Scale bars: (a, c) 120 mm, (b) 70 mm.
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and ¯uorescence was measured (excitation 485/emission 530) on a
SpectraMax Gemini microtiter plate reader (Molecular Devices
Corporation, Sunnyvale, CA) using Softmax Pro 3.0 software (Molecular
Devices Corporation). Each experiment was performed in six replicates.
The percent cleavage of the substrate by test samples was calculated and
graphed using Microsoft Excel.
A synthetic peptide comprising the cleavage site of the human PAR-2
(SKGRSLIGK) (Lourbakos et al, 1998) was labeled with the ¯uorophore
pair Edans/Dabsyl (Advanced Bioconcept, Montreal, Canada) and was
used as a substrate for PAR-2 serine protease activators. Cleavage of this
peptide with PAR-2 activators such as trypsin could be detected
¯uorescently (excitation 335 nm/emission 515 nm). 100 mM peptide
were incubated with test samples for 1 h at room temperature, protected
from light. Fluorescence was measured on SpectraMax Gemini microtiter
plate reader using Softmax Pro 3.0 software. Each experiment was
performed in six replicates. The percent of PAR-2 cleavage was
calculated and graphed using Microsoft Excel.
RESULTS
Localization of PAR-2 in normal human skin In normal
human skin PAR-2 expression was con®ned to keratinocytes in the
basal layer and just above the basal layer in a cytoplasmic and
peripheral membrane pattern. Keratinocytes above this layer, as
well as in the granular layer and corneal layer, were devoid of
PAR-2 expression (Fig 1a, b). Nuclear staining was observed
scattered throughout the epidermis within keratinocytes and in
follicular root sheath keratinocytes and was absent in sections
stained with preimmune serum (Fig 1c). Approximately 50% of
keratinocyte nuclei were labeled. To determine if the nuclear
staining observed was due to nonspeci®c antigen unmasking from
the antigen retrieval process, sections were stained with polyclonal
PAR-2 antibody with and without antigen retrieval. In the absence
of antigen retrieval, cytoplasmic and nuclear staining were retained
but both were diminished in intensity (data not shown). PAR-2
was also expressed in smooth muscles of blood vessels and pili
erector apparatus, endothelial cells, eccrine sweat glands, the basal
layer of sebaceous glands, and ®broblasts within the dermis.
Melanocytes did not express PAR-2 and there was no detectable
difference in PAR-2 distribution or staining intensity among the
three skin types (data not shown). Biopsies stained with preimmune
serum showed no staining (Fig 1c).
UVR upregulates expression of PAR-2 in human
skin Previous studies have shown that UVR induces the
expression of multiple different proteins in human skin. Of these,
p53, PCNA, and Ki-67 have been shown to be consistently
induced in skin in vivo in response to UVR (Hall et al, 1993;
Einspahr et al, 1996; Van der Vleuten et al, 1996). As a control for
UVR, we examined the expression of p53, PCNA, and Ki-67 in
irradiated subjects (Fig 2). Ki-67 was induced in the nuclei of cells
in all layers of the epidermis in a statistically signi®cant way in every
case studied 96 h postirradiation (p < 0.05). p53 was induced in the
nuclei of all cells in all layers of the epidermis at both doses of light
and time points in a statistically signi®cant way (p < 0.05). PCNA
was induced in the nuclei of all cells in all layers of the skin 96 h
following irradiation in a statistically signi®cant way (p < 0.05).
These data con®rm the physiologic effect of UVR in the study
subjects. Representative examples of data showing the effect of
UVR on PAR-2 distribution for each skin type are demonstrated
in Fig 3(a). The data are summarized in Table I.
The primary effect of UVR on PAR-2 expression consisted of de
novo expression of PAR-2 in keratinocytes in the middle and upper
layers of the epidermis (Fig 3a). In nonirradiated skin, PAR-2 is
expressed only in the basal and suprabasal keratinocytes in a
cytoplasmic and membranous pattern. Twenty-four hours follow-
ing UVR with 3 MED, and 96 h following 2 MED, PAR-2
expression is distributed throughout the entire epidermis. Skin
types II and III showed statistically signi®cant changes in PAR-2
expression following UVR at both doses and time points, but
subjects with skin type I only showed statistically signi®cant
changes in PAR-2 expression 96 h post-UVR (2 MED; Table I).
Whereas subjects with type I skin responded to UVR 24 h after a
dose of 3 MED with de novo expression of PAR-2 in keratinocytes
above the basal layer, these data did not reach statistical signi®cance
(p > 0.05). Figure 3(b) shows a representative example of a subject
with skin type I who showed upregulation of PAR-2 96 h
following 2 MED UVR but failed to show upregulation of PAR-2
24 h following 3 MED UVR. Staining intensities for PAR-2 were
also increased following exposure to UVR in most cases, although
this did not reach statistical signi®cance (p > 0.05, data not shown).
UVR upregulates PAR-2 protein expression in cultured
human keratinocytes To determine if UVR regulates PAR-2
expression in cultured human keratinocytes in vitro, cultured
keratinocytes were irradiated with a solar simulator at a dose of 2 J
per cm2, and PAR-2 expression was determined by
immuno¯uorescence microscopy 24 h later. Keratinocytes
showed uniform PAR-2 cytoplasmic staining in the absence of
UVR (Fig 4). Unstained cells were identi®ed as melanocytes by
their characteristic dendritic morphology. PAR-2
immunoreactivity in the perinuclear area (presumed Golgi
apparatus) was also noted. UVR induced a subjective increase in
intensity in PAR-2 expression in cultured keratinocytes (Fig 4b),
2-fold compared with nonirradiated cells (Fig 4a). Cells stained
with preimmune serum showed weak or no staining (Fig 4c). By
Western blotting, PAR-2 expression was increased in irradiated
keratinocytes compared with nonirradiated controls (Fig 5).
Sham-irradiated cells showed a faint immunoreactive band of
»55 kDa for PAR-2. In contrast, cells irradiated with 1 J per cm2,
2 J per cm2, and 4 J per cm2 displayed a strong immunoreactive
band of »55 kDa for PAR-2, which was clearly increased
compared with control cells. Coomassie stain of the gel con®rmed
equal loading of the lanes.
Proteases with PAR-2 cleavage activity are induced in
UVR-treated keratinocytes To determine if UVR induces
the release of PAR-2-activating proteases from cultured
keratinocytes, cells were irradiated with one of three different
Figure 2. UVR upregulates key biomarkers in subjects' biopsies.
To determine whether our subject population responded as expected to
UVR, p53, Ki-67, and PCNA staining were assessed on all biopsies.
Shown are representative examples of staining for these three markers in
control and UVR-treated skin. The subject population showed
upregulation of p53, Ki-67, and PCNA in a statistically signi®cant
manner. p53 is essentially absent in non-UVR-treated skin (a) but is
induced in the nucleus at all cell layers following UVR (b, 2 MED/
96 h). Ki-67 and PCNA showed scattered positive cells primarily in the
basal layer of control skin (c, e) and strong induction in the basal layer
following UVR (d, f, 2 MED/96 h). Scale bar: 120 mm.
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Figure 3. UVR upregulates PAR-2
expression in vivo. (a) Representative examples
of control and UVR-treated skin stained for
PAR-2 for each skin type and UVR dose are
shown. Controls (non-UVR) show predominantly
basal distribution of PAR-2 whereas
postirradiation PAR-2 immunoreactivity is present
throughout the epidermis. (b) Representative
example of a subject with type I skin who
demonstrated upregulation of PAR-2 96 h
following 3 MED UVR, but failed to show
upregulation of PAR-2 24 h following 2 MED
UVR. Scale bars: (a) 120 mm, (b) 40 mm.
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doses of UVR and 24 h later the culture media were analyzed for
protease activity and for PAR-2 cleavage activity. Figure 6
summarizes the results for analysis of secreted protease activity
and PAR-2 cleavage activity. There was a dose-dependent increase
in secreted protease activity with increasing doses of irradiation
(Fig 6a). Nonirradiated keratinocytes exhibited a constitutive level
of secreted protease activity, which showed a 50% increase after a
dose of 4 J per cm2. To determine if UVR-induced secreted
proteases have PAR-2 cleavage activity, culture supernatants from
irradiated cells were tested for their ability to cleave a synthetic
peptide of human PAR-2 containing the PAR-2 cleavage site using
a ¯uorometric assay (Fig 6b). Non-irradiated keratinocytes showed
constitutive levels of secreted PAR-2 protease cleavage activity,
which showed a dose-dependent increase with increasing doses of
UVR. Twenty-four hours following 1 J per cm2 and 2 J per cm2
there was a 41% and 42% increase, respectively, in PAR-2 peptide
cleavage. Twenty-four hours following 4 J per cm2 PAR-2 peptide
cleavage rose to 82% over control levels. In an effort to determine
the protease responsible for PAR-2 cleavage in UVR-treated
keratinocytes, Western blotting for trypsin, a serine protease known
to cleave PAR-2, was performed on cell lysates and supernatants
from irradiated keratinocytes. Culture supernatants were
concentrated using Centricon-10 ®lters and for each condition
the entire supernatant was resolved by SDS polyacrylamide gel
electrophoresis (SDS-PAGE) and probed for trypsin. No detectable
band was identi®ed in human keratinocyte cell lysates or culture
supernatants by Western blotting with the antibody used in this
study. A positive control (tryspin ethylenediamine tetraacetic acid)
was strongly reactive (data not shown).
DISCUSSION
In this report we studied the response of 36 subjects with either
type I, II, or III skin for the effect of UVR on PAR-2 expression.
For each subject, a careful history of sun exposure, reaction to sun,
and prior history of skin cancers was elicited, and control skin was
compared with irradiated skin for expression and distribution of
PAR-2, a novel receptor implicated in melanosome transfer and
in¯ammation. In nonirradiated normal skin PAR-2 was weakly
expressed in the basal and lower third of the epidermis, as well as in
follicular root sheath cells, smooth muscle of erector pili and vessels,
endothelial cells, eccrine sweat glands, the basal layer of sebaceous
glands, and some dermal dendritic cells. These results are similar to
most published observations (D'Andrea et al, 1998; Hou et al, 1998;
Seiberg et al, 2000a), in which the predominant PAR-2 staining
occurs in the lower epidermis. In contrast, Steinhoff et al (1999),
using immuno¯uorescence microscopy, reported that PAR-2
predominantly stains the granular cell layer of normal skin. They
detected staining of the basal layer and stratum Malphigi using the
more sensitive avidin±biotin peroxidase technique. The difference
between the staining observed in that report and ours may re¯ect
differences in specimen preparation, differences in antibodies used,
or both. In addition, specimens used in prior studies came from
sun-exposed areas, which may account for some of the staining
differences observed. The nuclear staining we observed has not
been reported previously and may be due to the use of antigen
retrieval. Antigen retrieval has been applied in immunohistochem-
ical studies to enhance antigen detection (Cuevas et al, 1994).
Although the mechanism of enhanced antigen retrieval via
microwave irradiation is not clear, it is believed to be mediated
via disruption of cross-linking proteins in a similar way to that
achieved by enzymatic predigestion. It may also result in
nonspeci®c staining through cross-reactivity of the antibody to
unmasked nonspeci®c epitopes. Nuclear staining was absent in
sections stained with preimmune serum and was present, albeit
diminished, in sections stained without antigen retrieval. Although
we cannot exclude the possibility that the nuclear staining observed
is nonspeci®c, more studies are required to better understand this
staining pattern.
We show that UVR signi®cantly changes the distribution of
PAR-2 protein expression in human skin in vivo. We observed de
novo expression of PAR-2 in keratinocytes in the upper layers of
the epidermis following irradiation, which contrasts with its normal
distribution to the lower third epidermal layer in nonirradiated
skin. PAR-2 upregulation was observed at both the 2 MED and 3
MED doses of irradiation, and at both time points. These doses and
time points were chosen because many acute effects of UVR on the
skin appear in 3±6 h, reach a peak between 12 and 24 h (such as
erythema and cytokine release), and proliferation effects are readily
evident at 96 h (Soter, 1990). Whereas both doses of irradiation
increased PAR-2 expression in the epidermis in a statistically
signi®cant way in type II and type III skin, PAR-2 upregulation
was more pronounced in the 2 MED/96 h samples compared with
the 3 MED/24 h samples. This may re¯ect the time necessary for
new mRNA synthesis and translation. Further, we show that
subjects with type I skin displayed statistically signi®cant differences
in UVR-related induction of PAR-2 expression compared with
subjects with skin types II and III. Speci®cally, subjects with type I
skin failed to show a statistically signi®cant upregulation in PAR-2
expression 24 h following 3 MED irradiation. These observations
suggest that differences in PAR-2 regulation in response to UVR
may be one factor in determining a person's ability to tan.
By immuno¯uorescence microscopy on cultured human kera-
tinocytes, PAR-2 was distributed in a cytoplasmic pattern with
prominent localization to the presumed Golgi apparatus without
detectable nuclear staining. These results are similar to those
reported by Bohm et al (1996a) who also demonstrated large pools
of PAR-2 in the Golgi apparatus in an epithelial cell line
Table I. PAR-2 expression is upregulated in human skin
epidermis after UVRa
3 MED/24 h 2 MED/96 h
Skin type (N) I (12) II (12) III (12) I (12) IIb (12) III (12)
Increased 6 8c 8 10 7 11
Unchanged 6 4 4 2 3 1
aThe data are presented as changes in PAR-2 distribution in UVR skin com-
pared with nonirradiated skin from the same patient taken at the same time.
Therefore, cases in which de novo expression of PAR-2 into the upper layers of
the epidermis was seen compared with control sections are designated as ``in-
creased''. Similarly, if no change in expression of PAR-2 in response to UVR
compared with control skin was observed this is represented as ``unchanged''.
bTwo subjects in this group at this data point were uninterpretable due to tech-
nical problems.
cBold, statistically signi®cant (p < 0.05).
Figure 4. PAR-2 is upregulated by UVR in human keratinocytes
in vitro. (a) Immuno¯uorescence microscopy of cultured human
keratinocytes stained for PAR-2, counterstained with DAPI, and viewed
with a ®lter to detect Texas Red and DAPI. Keratinocytes are uniformly
stained with antibodies to PAR-2 with concentration around the Golgi
apparatus (arrowhead). Unstained cells (arrow) were determined to be
melanocytes by their characteristic dendritic morphology. (b) Twenty-
four hours following UVR PAR-2 staining intensity has increased at
least 2-fold. (c) Cells stained with preimmune serum show little or no
staining. Scale bars: 40 mm.
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engineered to over-express human PAR-2. Because keratinocytes
were cultured in low Ca2+ medium, they were expected to be
proliferative rather than differentiated, as reported by others
(Hennings et al, 1980a, b). Therefore, it is not surprising that all
cultured keratinocytes expressed PAR-2 as these cells mimic in
many ways the phenotype of basal keratinocytes in vivo. We
detected a clear increase in staining intensity for PAR-2 following
irradiation of cultured keratinocytes within 24 h of a single 2 J per
cm2 dose of UVR. These results were con®rmed by Western
blotting of cell lysates of irradiated cells with a monoclonal antibody
to PAR-2. A clear increase in immunoreactive PAR-2 was
detected in cells irradiated with 1 J per cm2, 2 J per cm2, and 4 J
per cm2.´ Because we demonstrated that UVR induces PAR-2
expression in vivo and in vitro, we next determined whether UVR
of cultured keratinocytes would induce the secretion of a protease
with PAR-2 cleavage activity. UVR did indeed induce a dose-
dependent increase in secreted protease in cultured keratinocytes.
Further, a dose-dependent increase in PAR-2 cleavage activity was
also observed, strongly suggesting that UVR induces both increased
expression of PAR-2 and PAR-2 activation through upregulation
of a protease with PAR-2 cleavage activity.
Mast cell tryptase has been shown to activate PAR-2 in
keratinocytes in vitro and tryptase-containing mast cells are
increased in in¯ammatory skin conditions, which show upregulated
PAR-2 expression (Steinhoff et al, 1999). Previous studies have
shown that dermal mast cells are activated after irradiation resulting
in degranulation (Gilchrest et al, 1981). We observed increased
numbers of mast cells in subjects' skin biopsies following irradiation
and therefore it is likely that mast cell tryptase plays an important
role in PAR-2 activation in response to UVR (unpublished
observations). Based on our observation that UVR upregulates a
PAR-2 activating protease with PAR-2 cleavage activity in
cultured keratinocytes, it is likely that other proteases within the
epidermis are involved in UVR-induced PAR-2 activation. Other
tryspin-type serine proteases have been detected in human
keratinocytes, which may prove to cleave PAR-2. Potential
candidates include TLSP, a novel serine protease that is expressed
in keratinocytes (Yoshida et al, 1998), and squamous cell
chymotyrptic enzyme, both of which exhibit trypsin-like activity
(Sondell et al, 1994). Whereas UVR may upregulate the expression
or activity of a serine protease with PAR-2 cleavage activity, an
alternative possibility is that UVR-induced inhibition of a serine
protease inhibitor may account for the ability of UVR to activate
PAR-2 in our culture system. Abts et al (1997) identi®ed a UVR
repressible gene in HaCaT and human keratinocytes from psoriatic
epidermis. The gene product, termed hurpin (protease inhibitor
Figure 6. UVR-treated cultured human keratinocytes secrete a
protease with PAR-2 cleavage activity. (a) Culture supernatants of
UVR-treated keratinocytes were assessed for protease activity using the
EnzChek protease assay kit as described in Materials and Methods. Results
are expressed as percent increase in protease activity compared with
control (no UVR) 6 standard error of the mean. Control cells showed
baseline protease activity, which increased over 50% 24 h following a
single dose of 4 J per cm2 from a solar simulator. (b) Culture
supernatants from UVR-treated keratinocytes were assessed for PAR-2
cleavage activity using a ¯uorolabeled peptide containing the cleavage
site of PAR-2. Results are expressed as percent increase in PAR-2
cleavage activity compared with control (no UV) 6 standard error of the
mean. Control cells express a protease with PAR-2 cleavage activity,
which increased over 80% following a single dose of 4 J per cm2 from a
solar simulator.
Figure 5. UVR of cultured human keratinocytes results in a
dose-dependent increase in PAR-2 protein expression by Western
blotting. (a) Lysates of irradiated keratinocytes were separated by SDS-
PAGE and probed for PAR-2 with monoclonal antibodies against
human PAR-2. A 55 kDa band corresponding to the expected molecular
weight of PAR-2 was detected in sham-irradiated cell lysates. A clear
increase in PAR-2 was observed at 1 J per cm2 and was further increased
at 2 J per cm2. Levels of PAR-2 in cells irradiated with 4 J per cm2 were
similar to that seen in cells irradiated with 2 J per cm2. (b) The gel was
stained with Coomassie Brilliant Blue to con®rm equal loading of the
lanes.
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13), is a putative serine protease inhibitor in the ovalbumin family
of serpins. Although the target protease for hurpin is currently
unknown, it is possible that this or some other UV-regulated serine
protease inhibitor may play a role in PAR-2 activation in the skin
in response to UVR.
UVR modulates the function of a variety of epidermal and
dermal cells through induction and release of a complex network of
cytokines, chemokines, neuropeptides, adhesion molecules, and
other in¯ammatory mediators, resulting in diverse biologic effects
including erythema, edema, and pigmentation. It is interesting to
speculate that upregulation of PAR-2 levels by UVR may
contribute to the cytokine cascade observed in keratinocytes in
response to UVR in vivo. Hou et al (1998) has shown that activation
of PAR-2 stimulates interleukin-8 (IL-8) secretion by keratinocytes
in vitro. Wakita et al (1997) showed that activation of PAR-2 by a
murine agonist peptide induces gene expression for IL-6 and
GMCSF in cultured human keratinocytes. Therefore it is possible
that UVR upregulation of PAR-2 may in turn modulate synthesis
and secretion of cytokines such as IL-8, IL-6, and GMCSF by
keratinocytes in vivo.
The mechanism of UVR-induced PAR-2 upregulation remains
to be determined. Recent reports showing that IL-1a and TNF-a
upregulate PAR-2 expression in vitro, however, suggest that these
cytokines may be responsible for PAR-2 induction in response to
UVR in vivo. Human endothelial cells respond to treatment with
IL-1a or TNF-a by upregulation of PAR-2 mRNA 5±10-fold,
which occurs within 20 h and persists for up to 96 h in the
continued presence of the cytokine (Nystedt et al, 1996). This time
course is identical to that observed in PAR-2 upregulation in the
skin, in which upregulation occurred 24 and 96 h following UVR.
It is well documented that UVR induces keratinocytes to produce
and secrete cytokines including IL-1, IL-6, IL-8, and TNF
(reviewed in Kondo, 1999). The time course for secretion of
these cytokines precedes the peak induction of PAR-2 noted here.
Therefore it is possible that UVR-induced synthesis and secretion
of keratinocyte-derived IL-1 and TNF-a may participate in
upregulation of PAR-2. In support of this hypothesis are data
showing that PAR-2 is upregulated in in¯ammatory conditions in
the skin in vivo including lichen planus, where enhanced PAR-2
immunoreactivity was observed in the granular layer, and atopic
dermatitis and psoriasis vulgaris, in which PAR-2 immunoreactiv-
ity was detected throughout the entire epidermis (Steinhoff et al,
1999). Another potential role for PAR-2 may be in mediating
postin¯ammatory pigmentation, which occurs following a variety
of in¯ammatory skin diseases such as dermatitis and psoriasis. It is
possible that disordered regulation of PAR-2 in response to
cytokines released during the in¯ammatory process may result in
either increased uptake of melanosomes in neighboring keratino-
cytes, or even delayed or absent melanosome uptake. In the latter
case, melanosomes may be released into the dermis and
phagocytized by melanophages, resulting in the characteristic
histologic picture of postin¯ammatory pigmentation.
UVR has profound effects on skin pigmentation through a
variety of mechanisms. In reconstructed human epidermis, UVR
results in increased presence of melanosomes around keratinocyte
nuclei through increased melanocyte dendricity, melanin produc-
tion, and transport to keratinocytes (Murli et al, 2000). One model
of melanosome transfer is cytophagocytosis, in which the
melanocyte dendrite tip is phagocytized by the keratinocytes
(Cohen and Szabo, 1967; Wolff, 1973; Yamamoto and Bhawan,
1994). Following phagocytosis, melanosomes are taken up by
autophagic vacuoles, transported to the perinuclear space, and
degraded. PAR-2 has recently been shown to increase phagocytosis
of melanosomes in vitro and to induce skin darkening in vivo
through increased uptake of melanosomes (Seiberg et al, 2000a, b;
Sharlow et al, 2000). Because the antibody we used for
immunocytochemical staining of skin biopsies recognizes both
the active and the inactive form of the PAR-2 receptor, it is unclear
what proportion of newly expressed PAR-2 represents active
receptor. Our in vitro data showing that UVR induces protease
secretion with PAR-2 cleaving activity, however, suggests that
UVR both upregulates and activates PAR-2. UVR-induced de
novo expression and activation of PAR-2 may result in increased
uptake of melanosome-containing dendrite tips, accounting in part
for the well-known effects of UVR on skin pigmentation. As
PAR-2 has been shown to play an important role in both cutaneous
pigmentation and in¯ammation, it is possible that PAR-2, in
concert with other keratinocyte-derived factors, is involved in the
®nal common pathway of post-UVR in¯ammation and hyperpig-
mentation of the skin.
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